Research programme: locked nucleic acid oligonucleotides - Boehringer Ingelheim/Roche

Drug Profile

Research programme: locked nucleic acid oligonucleotides - Boehringer Ingelheim/Roche

Latest Information Update: 26 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim; Roche
  • Class Anti-inflammatories; Oligonucleotides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Inflammatory bowel diseases

Most Recent Events

  • 19 Dec 2017 Boehringer Ingelheim and Roche enter into a collaboration agreement for the development of locked nucleic acid oligonucleotides for Inflammatory bowel diseases
  • 19 Dec 2017 Early research in Inflammatory bowel disease in Switzerland, and Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top